EGM
CRVS icon

Engineers Gate Manager’s Corvus Pharmaceuticals CRVS Stock Holding History

Engineers Gate Manager’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
+36,019
New +$500K 0.01% 1459
2025
Q1 		– Sell
-84,612
Closed -$453K – 2227
2024
Q4 		$453K Buy
+84,612
New +$632K 0.01% 1490
2022
Q1 		– Sell
-11,814
Closed -$28K – 1927
2021
Q4 		$28K Buy
+11,814
New +$45.8K ﹤0.01% 1919

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Engineers Gate Manager's CRVS Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 36,019 shares worth $538K. The stake represents 0.01% of the portfolio and ranks #1459 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in CRVS as recently as Q4 2024.

Engineers Gate Manager first reported a position in CRVS in Q4 2021 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Engineers Gate Manager held 36,019 shares of Corvus Pharmaceuticals worth $538K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Engineers Gate Manager position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1459 holding.
  • Engineers Gate Manager first reported a position in Corvus Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.